Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
carvedilol phosphate + lisinopril
- Development stage
- Unknown
- Lead developer
- GSK
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Carvedilol phosphate + lisinopril is a combination of two antihypertensive agents used together to manage high blood pressure and heart failure. Carvedilol phosphate is a non-selective beta-adrenergic blocker with alpha-1 blocking activity (third-generation beta-blocker), which reduces heart rate and dilates blood vessels. Lisinopril is an angiotensin-converting enzyme (ACE) inhibitor that lowers blood pressure by inhibiting the conversion of angiotensin I to angiotensin II, leading to vasodilation and reduced aldosterone secretion. The combination may provide complementary benefits in improving endothelial function and reducing oxidative stress in patients with hypertension or heart failure[2][6]. Both drugs are commonly prescribed together for cardiovascular protection.
- Brand names
- Coreg CR + ZestrilCoreg CR + PrinivilCoreg CR + QbrelisCoreg CR + Zestoretic
- Other names
- carvedilol controlled-release plus lisinopril
02
Targets
ADRA1A (α1A)ACE (Angiotensin Converting Enzyme)ADRB2 (β2)ADRB1 (β1)
Beyond the preview
Go deeper on carvedilol phosphate + lisinopril.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on carvedilol phosphate + lisinopril.